Abstract:A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. Cancer Drug-Resistance Overview The development of targeted therapies has brought much promise to overcoming cancer as a compendium of different genomic diseases [1]. However, the success of such personalized therapies was quickly met with varying degrees of drug resistance. Therefore, it is instructive to study the mechanisms of drug resistance in parallel with the development of the drug itself, in anticipation that understanding the eventual drug resistance would result in strategies to overcome such outcomes. Both intrinsic and acquired drug resistance need to be addressed. ‘Intrinsic resistance’ indicates that resistance-mediating factors are present in tumor tissues before receiving treatment, while ‘acquired resistance’ refers to resistance mechanisms that develop after the drug treatment of tumors that are initially responsive. The distinction between these two broad categories of resistance is sometimes blurred by the heterogeneity of tumor tissues, because acquired resistance may be caused by the presence of a rare resistant subpopulation of cells in the original tumor [2]. The recent advances in genomic methods have greatly accelerated our understanding of cancer drug resistance. In this review, we briefly summarize the major biochemical and genetic mechanisms causing cancer drug resistance, and then focus primarily on the genomic approaches commonly used to reveal the genetic changes underlying those major mechanisms.

Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification

Molecular Insights into Cancer Drug Resistance from a Proteomics Perspective

Analysis of Tumor Drug Resistance-Associated Proteins by Proteomics Study

Proteomics for Identifying Mechanisms and Biomarkers of Drug Resistance in Cancer.

The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer

Proteomics for cancer drug design

Proteomics, Personalized Medicine and Cancer

A protracted war against cancer drug resistance

Advances of Proteomics Technologies for Multidrug-Resistant Mechanisms

Proteomic profiling predicts drug response to novel targeted anticancer therapeutics

When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective

Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts.

Pan-cancer proteogenomics expands the landscape of therapeutic targets

Expanding individualized therapeutic options via genoproteomics

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer

Systematic identification of genomic markers of drug sensitivity in cancer cells

Drug Response Modeling across Cancers: Proteomics vs. Transcriptomics

Whole-exome Sequencing Reveals Potential Mechanisms of Drug Resistance to FGFR3-TACC3 Targeted Therapy and Subsequent Drug Selection: Towards a Personalized Medicine.

Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

Proteomics approach to illustrate drug action mechanisms.

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic